ES2781090T3 - Formulaciones de olopatadina para administración nasal tópica - Google Patents
Formulaciones de olopatadina para administración nasal tópica Download PDFInfo
- Publication number
- ES2781090T3 ES2781090T3 ES15185071T ES15185071T ES2781090T3 ES 2781090 T3 ES2781090 T3 ES 2781090T3 ES 15185071 T ES15185071 T ES 15185071T ES 15185071 T ES15185071 T ES 15185071T ES 2781090 T3 ES2781090 T3 ES 2781090T3
- Authority
- ES
- Spain
- Prior art keywords
- olopatadine
- phosphate
- composition
- compositions
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 title claims abstract description 78
- 229960004114 olopatadine Drugs 0.000 title claims abstract description 75
- 238000009472 formulation Methods 0.000 title description 26
- 230000000699 topical effect Effects 0.000 title description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 64
- 239000011780 sodium chloride Substances 0.000 claims abstract description 32
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract description 14
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 239000012458 free base Substances 0.000 claims abstract description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract description 3
- 229940111688 monobasic potassium phosphate Drugs 0.000 claims abstract description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims abstract description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims abstract description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229940001496 tribasic sodium phosphate Drugs 0.000 claims abstract description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims abstract description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 229940111685 dibasic potassium phosphate Drugs 0.000 claims description 2
- 229940062627 tribasic potassium phosphate Drugs 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 description 41
- 239000000243 solution Substances 0.000 description 27
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 24
- 239000008363 phosphate buffer Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 230000000007 visual effect Effects 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229910000397 disodium phosphate Inorganic materials 0.000 description 10
- 235000019800 disodium phosphate Nutrition 0.000 description 10
- 230000003139 buffering effect Effects 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000007922 nasal spray Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229940097496 nasal spray Drugs 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- -1 inorganic acid salts Chemical class 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 5
- 229960005426 doxepin Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000011045 prefiltration Methods 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 229940124274 edetate disodium Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000001302 tertiary amino group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000008863 intramolecular interaction Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 2
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000002479 acid--base titration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940073464 benzododecinium bromide Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940097078 patanol Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15185071.6A EP2977042B1 (en) | 2007-02-07 | 2007-02-07 | Olopatadine formulations for topical nasal administration |
| PCT/US2007/003285 WO2008097220A1 (en) | 2007-02-07 | 2007-02-07 | Olopatadine formulations for topical nasal administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2781090T3 true ES2781090T3 (es) | 2020-08-28 |
Family
ID=38542957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15185071T Active ES2781090T3 (es) | 2007-02-07 | 2007-02-07 | Formulaciones de olopatadina para administración nasal tópica |
| ES07750153.4T Active ES2557939T3 (es) | 2007-02-07 | 2007-02-07 | Formulaciones de olopatadina para administración nasal tópica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07750153.4T Active ES2557939T3 (es) | 2007-02-07 | 2007-02-07 | Formulaciones de olopatadina para administración nasal tópica |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2977042B1 (enExample) |
| JP (1) | JP5149308B2 (enExample) |
| KR (1) | KR20100014858A (enExample) |
| CN (1) | CN101621989A (enExample) |
| AU (1) | AU2007346121B2 (enExample) |
| BR (1) | BRPI0721255B8 (enExample) |
| CA (1) | CA2677631C (enExample) |
| DK (1) | DK2114367T3 (enExample) |
| ES (2) | ES2781090T3 (enExample) |
| HU (1) | HUE026162T2 (enExample) |
| MX (1) | MX2009008548A (enExample) |
| PL (1) | PL2114367T3 (enExample) |
| PT (1) | PT2114367E (enExample) |
| SI (1) | SI2114367T1 (enExample) |
| WO (1) | WO2008097220A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011001317A (ja) * | 2009-06-19 | 2011-01-06 | Fumakilla Ltd | 鼻用洗浄剤 |
| PT2453872E (pt) * | 2009-07-17 | 2013-10-30 | Alcon Res Ltd | Regime de pulverização nasal de olopatadina para crianças |
| KR101271925B1 (ko) * | 2011-02-10 | 2013-06-05 | 비. 김 로버트 | 미네랄 알칼리수 |
| TW201336527A (zh) * | 2012-02-10 | 2013-09-16 | Alcon Res Ltd | 具增強的穩定性之水性藥學組成物 |
| CN103830219A (zh) * | 2012-11-20 | 2014-06-04 | 深圳大佛药业有限公司 | 一种稳定的奥洛他定组合物 |
| CN114980881A (zh) * | 2019-12-06 | 2022-08-30 | 东兴药品工业株式会社 | 包含奥洛他定的鼻用组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923892A (en) | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
| GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| JPS6310784A (ja) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
| JP3662944B2 (ja) * | 1993-08-24 | 2005-06-22 | 協和醗酵工業株式会社 | 点鼻剤 |
| US5641805A (en) | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
| PT1250133E (pt) * | 2000-01-25 | 2005-05-31 | Alcon Inc | Composicoes antialergicas oftalmicas adequadas a utilizacao com lentes de contacto |
| TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
| CN1297275C (zh) * | 2002-11-12 | 2007-01-31 | 爱尔康公司 | 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途 |
| AU2005309951B2 (en) | 2004-11-24 | 2011-07-07 | Alcon, Inc. | Method of delivering nasal spray |
-
2007
- 2007-02-07 HU HUE07750153A patent/HUE026162T2/en unknown
- 2007-02-07 WO PCT/US2007/003285 patent/WO2008097220A1/en not_active Ceased
- 2007-02-07 PL PL07750153T patent/PL2114367T3/pl unknown
- 2007-02-07 KR KR1020097017832A patent/KR20100014858A/ko not_active Ceased
- 2007-02-07 EP EP15185071.6A patent/EP2977042B1/en active Active
- 2007-02-07 CA CA2677631A patent/CA2677631C/en active Active
- 2007-02-07 ES ES15185071T patent/ES2781090T3/es active Active
- 2007-02-07 PT PT77501534T patent/PT2114367E/pt unknown
- 2007-02-07 BR BRPI0721255A patent/BRPI0721255B8/pt active IP Right Grant
- 2007-02-07 AU AU2007346121A patent/AU2007346121B2/en active Active
- 2007-02-07 SI SI200731711T patent/SI2114367T1/sl unknown
- 2007-02-07 ES ES07750153.4T patent/ES2557939T3/es active Active
- 2007-02-07 EP EP07750153.4A patent/EP2114367B1/en active Active
- 2007-02-07 DK DK07750153.4T patent/DK2114367T3/en active
- 2007-02-07 MX MX2009008548A patent/MX2009008548A/es active IP Right Grant
- 2007-02-07 CN CN200780051017A patent/CN101621989A/zh active Pending
- 2007-02-07 JP JP2009549052A patent/JP5149308B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2977042B1 (en) | 2020-01-01 |
| CN101621989A (zh) | 2010-01-06 |
| EP2114367B1 (en) | 2015-11-04 |
| JP2010518075A (ja) | 2010-05-27 |
| BRPI0721255B8 (pt) | 2021-05-25 |
| BRPI0721255B1 (pt) | 2019-08-27 |
| BRPI0721255A2 (pt) | 2013-01-01 |
| PT2114367E (pt) | 2016-02-01 |
| EP2114367A1 (en) | 2009-11-11 |
| HK1217090A1 (en) | 2016-12-23 |
| DK2114367T3 (en) | 2015-12-07 |
| AU2007346121A1 (en) | 2008-08-14 |
| CA2677631A1 (en) | 2008-08-14 |
| KR20100014858A (ko) | 2010-02-11 |
| SI2114367T1 (sl) | 2016-01-29 |
| JP5149308B2 (ja) | 2013-02-20 |
| AU2007346121B2 (en) | 2012-08-23 |
| HUE026162T2 (en) | 2016-05-30 |
| ES2557939T3 (es) | 2016-01-29 |
| EP2977042A1 (en) | 2016-01-27 |
| PL2114367T3 (pl) | 2016-03-31 |
| MX2009008548A (es) | 2009-08-18 |
| WO2008097220A1 (en) | 2008-08-14 |
| CA2677631C (en) | 2014-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8399508B2 (en) | Olopatadine formulations for topical nasal administration | |
| ES2432502T3 (es) | Pauta terapéutica de pulverización nasal de olopatadina para niños | |
| ES2238574T3 (es) | Formulaciones de olopatadina para administracion topica. | |
| ES2264266T3 (es) | Preparaciones liquidas acuosas. | |
| ES2781090T3 (es) | Formulaciones de olopatadina para administración nasal tópica | |
| ES2809304T3 (es) | Formulaciones oftálmicas estabilizadas de galactomanano | |
| ES2404086T3 (es) | Formulaciones tópicas en solución que contienen un corticosteroide y una ciclodextrina | |
| WO1995031179A1 (es) | Disolucion oftalmica a base de diclofenaco y tobramicina y sus aplicaciones | |
| ES2236180T3 (es) | Composiciones oftalmicas antialergicas adecuadas para uso con lentes de contacto. | |
| JP6818019B2 (ja) | レファムリンの注射可能医薬組成物 | |
| ES2247372T3 (es) | Composicion oftalmica que contiene n-acetilcisteina para el tratamiento del sindrome de ojos secos. | |
| JP2916340B2 (ja) | ナトリウムクロモグリケートの水性医薬組成物 | |
| JPS63174930A (ja) | キノロンカルボン酸の水性組成物 | |
| JPH06247872A (ja) | 高濃度ｔｃｆ製剤 | |
| ES2988534T3 (es) | Composición que contiene de manera estable una molécula de ácido nucleico de cadena sencilla que suprime la expresión del gen TGF-ß1 | |
| HK1217090B (en) | Olopatadine formulations for topical nasal administration | |
| JPH0383931A (ja) | 低刺激性ｇｒｆ経鼻投与製剤 | |
| BRPI0608375A2 (pt) | utilizacão de azitromicina, medicamento para o tratamento das conjuntivites bacterianas, processo de fabricacão de um medicamento de tratamento das infeccões oculares e acondicionamento para um medicamento para o tratamento das conjuntivites bacterianas |